QILU PHARMACEUTICAL CO., LTD.

W1D02
China Mainland
Company Profile
  • Year Established: 1958
  • Total Number of Staff: more than 1000
  • Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
  • Business Type: All
  • R&D Capacity: Own Brand
  • Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Qilu always commits itself to offering high-quality & trustworthy medicines to the world and improving people’s well-being. It is the first Chinese company to obtain both USFDA and EDQM approval for sterile APIs. Its Finished Formulations and APIs have been approved by USFDA, EMA, TGA, MHRA, PMDA, etc. Qilu maintains a robust and sustainable growth in global markets while consistently foraying into new geographies to further fortify its position globally. With a well-established domestic and overseas sales network, you may find Qilu’s footprints across the world.

Year Established: 1958

Total Number of Staff: more than 1000

Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service

Business Type: All

R&D Capacity: Own Brand

Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Top Products
Copyright 2006-2022 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182
Powered by